Literature DB >> 32345621

Comparative Pharmacokinetics of Δ9-Tetrahydrocannabinol in Adolescent and Adult Male Mice.

Alexa Torrens1, Valentina Vozella1, Hannah Huff1, Brandon McNeil1, Faizy Ahmed1, Andrea Ghidini1, Stephen V Mahler1, Marilyn A Huestis1, Aditi Das1, Daniele Piomelli2.   

Abstract

We investigated the pharmacokinetic properties of Δ9-tetrahydrocannabinol (Δ9-THC), the main psychoactive constituent of cannabis, in adolescent and adult male mice. The drug was administered at logarithmically ascending doses (0.5, 1.6, and 5 mg/kg, i.p.) to pubertal adolescent (37-day-old) and adult (70-day-old) mice. Δ9-THC and its first-pass metabolites-11-hydroxy-Δ9-THC and 11-nor-9-carboxy-Δ9-THC (11-COOH-THC)-were quantified in plasma, brain, and white adipose tissue (WAT) using a validated isotope-dilution liquid chromatography/tandem mass spectrometry assay. Δ9-THC (5 mg/kg) reached 50% higher circulating concentration in adolescent mice than in adult mice. A similar age-dependent difference was observed in WAT. Conversely, 40%-60% lower brain concentrations and brain-to-plasma ratios for Δ9-THC and 50%-70% higher brain concentrations for Δ9-THC metabolites were measured in adolescent animals relative to adult animals. Liver microsomes from adolescent mice converted Δ9-THC into 11-COOH-THC twice as fast as adult microsomes. Moreover, the brains of adolescent mice contained higher mRNA levels of the multidrug transporter breast cancer resistance protein, which may extrude Δ9-THC from the brain, and higher mRNA levels of claudin-5, a protein that contributes to blood-brain barrier integrity. Finally, administration of Δ9-THC (5 mg/kg) reduced spontaneous locomotor activity in adult, but not adolescent, animals. The results reveal the existence of multiple differences in the distribution and metabolism of Δ9-THC between adolescent and adult male mice, which might influence the pharmacological response to the drug. SIGNIFICANCE STATEMENT: Animal studies suggest that adolescent exposure to Δ9-tetrahydrocannabinol (Δ9-THC), the intoxicating constituent of cannabis, causes persistent changes in brain function. These studies generally overlook the impact that age-dependent changes in the distribution and metabolism of the drug might exert on its pharmacological effects. This report provides a comparative analysis of the pharmacokinetic properties of Δ9-THC in adolescent and adult male mice and outlines multiple functionally significant dissimilarities in the distribution and metabolism of Δ9-THC between these two age groups.
Copyright © 2020 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32345621      PMCID: PMC7318794          DOI: 10.1124/jpet.120.265892

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  38 in total

Review 1.  The Impact of Exposure to Cannabinoids in Adolescence: Insights From Animal Models.

Authors:  Tiziana Rubino; Daniela Parolaro
Journal:  Biol Psychiatry       Date:  2015-08-07       Impact factor: 13.382

2.  Δ9-Tetrahydrocannabinol changes the brain lipidome and transcriptome differentially in the adolescent and the adult.

Authors:  Emma Leishman; Michelle Murphy; Ken Mackie; Heather B Bradshaw
Journal:  Biochim Biophys Acta Mol Cell Biol Lipids       Date:  2018-02-08       Impact factor: 4.698

3.  L-Borneol induces transient opening of the blood-brain barrier and enhances the therapeutic effect of cisplatin.

Authors:  Yi Yin; Liu Cao; Hongfei Ge; Wangsheng Duanmu; Liang Tan; Jichao Yuan; Chen Tunan; Fei Li; Rong Hu; Fabao Gao; Hua Feng
Journal:  Neuroreport       Date:  2017-06-14       Impact factor: 1.837

4.  Binding of delta-1-tetrahydrocannabinol to human plasma proteins.

Authors:  M Wahlqvist; I M Nilsson; F Sandberg; S Agurell
Journal:  Biochem Pharmacol       Date:  1970-09       Impact factor: 5.858

Review 5.  Cannabis and adolescent brain development.

Authors:  Dan I Lubman; Ali Cheetham; Murat Yücel
Journal:  Pharmacol Ther       Date:  2014-11-20       Impact factor: 12.310

Review 6.  The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin.

Authors:  R G Pertwee
Journal:  Br J Pharmacol       Date:  2007-09-10       Impact factor: 8.739

7.  Reintoxication: the release of fat-stored delta(9)-tetrahydrocannabinol (THC) into blood is enhanced by food deprivation or ACTH exposure.

Authors:  N Gunasekaran; L E Long; B L Dawson; G H Hansen; D P Richardson; K M Li; J C Arnold; I S McGregor
Journal:  Br J Pharmacol       Date:  2009-08-14       Impact factor: 8.739

Review 8.  Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review.

Authors:  Stephen M Stout; Nina M Cimino
Journal:  Drug Metab Rev       Date:  2013-10-25       Impact factor: 4.518

Review 9.  Claudin-5: gatekeeper of neurological function.

Authors:  Chris Greene; Nicole Hanley; Matthew Campbell
Journal:  Fluids Barriers CNS       Date:  2019-01-29

10.  Fast and Sensitive Quantification of Δ9-Tetrahydrocannabinol and Its Main Oxidative Metabolites by Liquid Chromatography/Tandem Mass Spectrometry.

Authors:  Valentina Vozella; Cristina Zibardi; Faizy Ahmed; Daniele Piomelli
Journal:  Cannabis Cannabinoid Res       Date:  2019-06-14
View more
  8 in total

1.  Pharmacokinetic and pharmacodynamic properties of aerosolized ("vaped") THC in adolescent male and female rats.

Authors:  C M Ruiz; A Torrens; V Lallai; E Castillo; L Manca; M X Martinez; D N Justeson; C D Fowler; D Piomelli; S V Mahler
Journal:  Psychopharmacology (Berl)       Date:  2021-09-08       Impact factor: 4.530

2.  Administration of Δ9-Tetrahydrocannabinol Following Controlled Cortical Impact Restores Hippocampal-Dependent Working Memory and Locomotor Function.

Authors:  Shijie Song; Xiaoyuan Kong; Bangmei Wang; Juan Sanchez-Ramos
Journal:  Cannabis Cannabinoid Res       Date:  2021-11-05

3.  Adolescents are more sensitive than adults to acute behavioral and cognitive effects of THC.

Authors:  Conor H Murray; Zhengyi Huang; Royce Lee; Harriet de Wit
Journal:  Neuropsychopharmacology       Date:  2022-02-02       Impact factor: 8.294

4.  Pharmacokinetics and central accumulation of delta-9-tetrahydrocannabinol (THC) and its bioactive metabolites are influenced by route of administration and sex in rats.

Authors:  Samantha L Baglot; Catherine Hume; Gavin N Petrie; Robert J Aukema; Savannah H M Lightfoot; Laine M Grace; Ruokun Zhou; Linda Parker; Jong M Rho; Stephanie L Borgland; Ryan J McLaughlin; Laurent Brechenmacher; Matthew N Hill
Journal:  Sci Rep       Date:  2021-12-14       Impact factor: 4.379

Review 5.  Pharmacokinetics of Cannabis and Its Derivatives in Animals and Humans During Pregnancy and Breastfeeding.

Authors:  Anaëlle Monfort; Ema Ferreira; Grégoire Leclair; Gregory Anton Lodygensky
Journal:  Front Pharmacol       Date:  2022-07-12       Impact factor: 5.988

6.  An Ultra-Low Dose of ∆9-Tetrahydrocannabinol Alleviates Alzheimer's Disease-Related Cognitive Impairments and Modulates TrkB Receptor Expression in a 5XFAD Mouse Model.

Authors:  Keren Nitzan; Leah Ellenbogen; Ziv Bentulila; Dekel David; Motty Franko; Emanuela P Break; Michal Zoharetz; Alon Shamir; Yosef Sarne; Ravid Doron
Journal:  Int J Mol Sci       Date:  2022-08-21       Impact factor: 6.208

7.  Adolescent THC Treatment Does Not Potentiate the Behavioral Effects in Adulthood of Maternal Immune Activation.

Authors:  Todd M Stollenwerk; Cecilia J Hillard
Journal:  Cells       Date:  2021-12-11       Impact factor: 6.600

8.  Evaluation of the Possible Anticonvulsant Effect of Δ9-Tetrahydrocannabinolic Acid in Murine Seizure Models.

Authors:  Melissa J Benson; Lyndsey L Anderson; Ivan K Low; Jia Lin Luo; Richard C Kevin; Cilla Zhou; Iain S McGregor; Jonathon C Arnold
Journal:  Cannabis Cannabinoid Res       Date:  2020-09-09
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.